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The risks and benefits of a low protein—essential amino acid—keto acid
diet. Twelve patients with progressive renal failure were placed on a
very low protein diet supplemented by an essential amino acid—keto
acid mixture for six to twelve months. Total daily intake was 0.04 g
nitrogen/kg and 50 kcal/kg. Eight subjects had a significant change in the
slope of reciprocal plasma creatinine, becoming less steep and in two
cases positive. GFR did not improve, but in four patients the decline
over twelve months was less than 0.5 muter/mm. There were significant
falls in blood and urinary urea, serum phosphate P'FH and calcium X
phosphate product. Body wt decreased during the first three months.
Arm muscle circumference fell by 0.9 cm (P < 0.005). Serum albumin
and transferrin levels did not change significantly. Muscle mass and
plasma creatinine fell simultaneously in several patients. Creatinine
excretion per kg muscle mass, assessed anthropometrically, declined
by 21% in the first three months. This diet may slow the decline in renal
function in a proportion of patients. However, muscle mass can be lost.
Serum protein levels do not accurately reflect nutritional changes. A fall
in plasma creatinine may not be due to improved GFR but instead to
altered creatinine metabolism.
Low protein diets have been used for many years for symp-
tomatic relief of uremic symptoms. In an attempt to improve the
uremic state various combinations of essential amino acids and
their keto acid analogues (EAA/KAA) have been given as
supplements to diets low in nitrogen [1—5].
Recently it has been claimed that low protein diets may slow
the progression of renal failure [6, 7]. The evidence for a
protective effect of a low protein intake is striking in experi-
mental renal failure produced in rats by subtotal nephrectomy
[8] or glomerulonephritis [9]. A number of reports have ap-
peared which suggest there may be a similar effect in man
[10—14] but to date there has been only one attempt at a
prospective randomly allocated trial in human renal disease
[15].
Barsotti et al [16] reported that a very low protein diet
supplemented by an essential amino acid/keto acid mixture
appeared to slow or in some cases completely halt the progres-
sion of advanced renal failure. If decline in renal function can
indeed be arrested by such regimes, they would prove to be of
enormous importance in both human and economic terms. The
results of Barsotti et al were sufficiently striking to demand
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urgent confirmation. It also seemed important that before such
a regime was used to treat large numbers of patients, there
should be an assessment of the possible risks as well as of
benefits. We, therefore, investigated the effects of a very similar
diet on a comparable group of patients. In addition to reporting
changes in renal function, we also present detailed information
on the metabolic and nutritional consequences of this regime
together with more limited information on subjective responses.
Methods
Patients
Adult patients with chronic renal failure were selected on the
following criteria:
1. The presence of progressive chronic renal failure as judged
by a declining slope of reciprocal plasma creatinine. The
slope was plotted from a minimum of six separate measure-
ments over at least 16 months.
2. The absence of any reversible factor such as salt depletion or
untreated hypertension.
3. The probability of the need for renal replacement therapy
within one year as judged by projection of the reciprocal
plasma creatinine. This event was arbitrarily assumed to be
at a point when plasma creatinine reached between 1000 and
1500 mole/liter.
Nineteen patients fulfilling these criteria were started on the
regime. Twelve patients followed it for over six months each,
with a mean time on the diet of 12.25 months (range 6 to 24)
giving a total of 147 patient months of treatment. Potential
subjects were informed as to the experimental nature of the
regime and of the likelihood of their needing renal replacement
therapy in the near future. Patients whose renal function
subsequently became inadequate were started on dialysis when
appropriate and all are still alive.
Approval for this study was given by the Cardiff Division of
Medicine Ethical Committee.
Diet and drugs
A similar regime to the one reported by Barsotti et al [16] was
used, the main difference being the increased calorie content of
our diet. A very low protein intake (0.032 glkglday of nitrogen)
was supplied almost entirely as vegetable protein. This was
supplemented by an EAA/KAA mixture [5, 16]. Details of the
complete daily intake including the EAA/KAA mixture are
given in Table 1. In order to improve the range and palatability
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Table 1. Daily dietary content
Table 2. Daily intake per kg body wt essential amino acid—keto acid analogue mixture
Amino acids
L-lysinemonoacetate
L-tryptophan
L-threonine
L-histidine
L-tyrosine
Total N in mixture
5.3
12,5
9.0
7.0
Analogues
Ca-DL-3-Methyl-2-oxo-valerianatc
(ketoisoleucine)
Ca-4-Methyl-2-oxo-valerianate
(ketoleucine)
Ca-2-oxo-3-phenyl-propionatc
(ketophenylalanine)
Ca-3-Methyl-2-oxo-butyrate
(ketovaline)
Ca-DL-2-Hydroxy-4-methylthio-butyrate
(hydroxymethionine)
8.4 mg/kg
mg/kg
15.6
23.5
15.8
20.0
13.7
of the diet the patients were issued with a specially prepared
vegetarian cook book (JM). The details of the patients' diets
were calculated on an individual basis. Four of the patients who
were considerably in excess of their desired wt (>6 kg heavier)
were given a dietary allowance based on the desired wt. The
analysis of the EAA/KAA mixture is shown in Table 2. This
mixture came as a powder which was dissolved in water to
make an orange flavoured drink (Scientific Hospital Supplies,
Ltd., Liverpool, England). In addition patients received the
following supplements: ferrous sulphate, 200 mg daily; zinc
sulphate, 220 mg twice weekly; hydroxycobalamin, 1000 p.g
every three months; and, Ailbee with C, 1 tablet daily contain-
ing 15 mg thiamine, 10 mg riboflavine, 50mg nicotinamide, 5 mg
pyridoxine, 10 mg calcium pantothenate and 300 mg ascorbic
acid. Hypotensive drugs and fruscmide were prescribed as
appropriate for each individual. If the patient was taking
aluminum hydroxide at the start of the trial, the dosage was left
unchanged for at least three months. Patients not taking this
drug only received it after three months if serum phosphate
remained above the upper limit of normal. Six patients were
prescribed calcium carbonate as an alternative phosphate low-
ering agent. Alfacalcidol (1 a-hydroxycholecalciferol) had pre-
viously been given to three patients for hypocalcemia. This was
continued until serum calcium was normal.
Following the start of the trial, patients were seen at monthly
intervals for review by both a clinician and a dietitian.
Dietary compliance was assessed by means of a monthly
discussion with the dietitian (JM) who also interviewed the
spouse where appropriate. Blood samples and a 24 hr urine
collection were obtained for laboratory analysis. Changes in
blood and urinary urea were also employed as indices of
compliance.
Laborato,y measurements
The following blood measurements were made using standard
laboratory procedures: urea, electrolytes, creatinine, calcium,
phosphate, albumin, and full blood count. Total calcium was
corrected for serum albumin concentration by 0.02 mmole/liter
for each g/liter of albumin above or below 40 g/liter. Parathyroid
hormone was measured by immunoradiometric [17] assay using
an antiserum recognizing the intact PTH molecule. Transferrin
was measured by reaction with a monospecific antibody as
assessed by rate nephelometry.
Twenty-four hr urine samples were assayed for urea, creati-
nine and protein. Changes in renal function were assessed by
the slope of reciprocal plasma creatinine, creatinine clearance
and combined urea and creatinine clearance when
GFR C11 + Ccr [18].
Nutritional assessment
At the start of the diet patients' height, weight, triceps
skinfold thickness (TSF) and mid-arm circumference (MAC)
were measured. All except height were remeasured at each
monthly visit. The TSF was used as an assessment of body fat.
The MAC was converted into a measure of body muscle by the
following formula:
I. Mid-arm muscle circumference (MAMC) = MAC — (IT X
TSF).
Food
0.032
Powder
N content
g/kg body wt
Carbohydrate
Vegetable carbohydrate
Low protein products
Pure carbohydrate (e.g., Hycal)
Fat
Low protein products
Margarine
Corn oil
Protein
Total energy, Kcals/kg bod.v wt
Calcium mmole/kg body WI
Phosphate, mg
24.75 5.25
6.19
7.43
11.14
19.2
4.8
7.2
7.2
0.8
44.75 5.25
0.13 0.26
'Fotal
0.04
protein 'equivalent' = 0.25
30 (60%)
19.2 (38.4%)
0.8 (1.6%)
50
0.39
<500
mg/kg
24.5
2
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Table 3. Clinical and biochemical details of patients taking the diet
Patient Age Sex Diagnosis Wt, kg
Previous diet
g protein/day
Plasma creatinine
pnole/liter
1 44 F Chronic pyelonephritis
Staghorn calculi
44.4 60 735
2 28 F Reflux nephropathy 43.6 Free 1432
3 61 M IgA nephropathy 78.3 40 738
4 43 M Polycystic 75.8 40 1222
5 36 F Mesangiocapillary
Glomerulonephritis
58.0 Free 669
6 52 M Chronic renal failure
? cause
83.4 Free 856
7 46 M Polycystic 73.4 40 1166
8 45 M Polycystic 81.6 Free 975
9 50 F Polycystic 76.7 Free 594
10 47 F Polycystic 57.6 Free 706
11 52 M Hypertension 84.6 40 745
12 43 F Polycystic 75.0 Free 949
2. Total muscle mass (kg) = height
[0.0264 + 0.0029 (MAC — ir X TSF)2
The figure of 6.5 represents an estimate of bone area in the
upper arm for women. For male subjects a value of 10 was used
instead [20]. As a further guide to nutrition the serum values for
albumin and transferrin were measured monthly.
Statistical analysis
Changes in biochemical and nutritional measurements were
assessed at three month intervals using Student's paired t-test
(two tailed). The effect of the diet on the slope of the reciprocal
of plasma creatinine was measured by the formula
—
slope 1 — slope 2
'SD12 + SD22
Results
Clinical response
Initially 19 patients fulfilling our criteria were offered the diet.
Six patients began treatment but were withdrawn from the
study within three months because of nausea induced by the
EAA/KAA mixture in three, fractured leg (unrelated) in one,
and rapidly deteriorating renal function associated with high
serum aluminium levels in two patients on an unaltered high
intake of aluminium hydroxide. One additional patient eventu-
ally admitted total non-compliance. Her results are not consid-
ered further.
The remaining 12 patients took the diet for a minimum of six
months each. Details of these participants are shown in Table 3.
Patients continued the regime for up to 12 months and were
only discontinued if on clinical and biochemical grounds renal
replacement therapy was thought necessary. Six patients were
transferred to dialysis, one at 7 months, one at 10 months and
the remaining four after at least 12 months. At the time of
writing, two patients remain on the regime after more than two
years, (patient numbers 5 and 6). Dietary assessment confirmed
Renal function
Prior to starting the trial, renal function as assessed by
reciprocal plasma creatinine had been deteriorating steadily in
all the patients. The minimum correlation coefficient for the
previous reciprocal plasma creatinine for any patient was
—0.76, and nine patients had values of —0.92 or greater. The
subsequent slope of the reciprocal changed significantly in eight
patients becoming less steep, P values ranging from <0.05to <
0.001 (Fig. 1). The correlation coefficient of reciprocal creati-
nine against time ranged from + 0.52 to —0.91 after starting the
diet. In two patients (numbers 5 and 6) the calculated regression
line became positive during a 12 month period on the diet. Ten
of the 12 patients had a fall in their plasma creatinine concen-
tration of between 66 and 397 p mole/liter during the first six
months of treatment (Fig. I). The delay in plasma creatinine
concentrations reaching a higher value than at the start of the
treatment varied from 0 to greater than 12 months.
Creatinine clearance fell by 1.5 1.5 mliter/min for the group
as a whole over the first six months of the diet P < 0.005, but
the changes over the first and second quarters of the trial did not
reach statistical significance. For the seven patients who took
the diet for at least 12 months, creatinine clearance decreased
by 1.7 1.7 mliter/min during this period, P <0.05. However,
four patients had effectively stable function, creatinine clear-
ance changing by less than 0.5 mliter/min in the year.
The values for combined urea and creatinine clearance
showed similar changes. During the first six months the com-
bined clearance fell by 0.9 1.2 mliter/min, P < 0.05. The
seven patients studied for a year had a fall of 1.3 1.6
mliter/min, NS. The same four patients showing little change in
that patients consumed all the keto acid mixture and did not
take any extra protein.
6.51 [19]. A striking feature during this study was the sense of well
being felt by the patients. Prior to starting the diet many had
lethargy, nausea and anorexia. After about two months most
patients felt much better and spontaneously commented on
their improved state. This feeling was maintained even in the
presence of declining renal function. We have not however
attempted to quantify the severity of symptoms felt by our
patients.
The degrees of freedom were given by the number of points
on the slopes minus 2.
Where appropriate results are expressed as the mean SD.
-12 6 0 6 12 —12 —6 0 6 12
Patient 5 Patient 6\ 4!'•••••'
P c 0.001
—12 -6 0 6 12
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Fig. 1. Reciprocal plasma creatinine values (mmolelliter) for patients I through 12 before and after commencing the diet. The vertical hatched line(i) represents the start of the study. The calculated regression line (I) is for values prior to the diet. P values represent the significant differences
between the calculated regression lines for reciprocal creatinine before and after starting the diet.
creatinine clearance had the least decrease in combined clear-
ance (<0.5 mliter/min), one (patient number 4) having an
apparent increase in function. Figure 2 shows the measured
values when starting the diet and at final assessment.
Metabolic changes
Blood urea fell dramatically in the first three months in all
patients, Pc 0.001. The mean value decreased from 31.1 6.8
mmole/liter to 13.3 6.5 mmole/liter. There was a rise to 19.2
mmole/liter from three to six months, P c 0.005. In those
patients who were followed for at least 12 months, the mean
drop of 10.7 mmole/liter over the year was still significant, P <
0.05.
Urine urea excretion fell in parallel with the blood urea, total
output decreasing by 115 61 mmole/24 hr in the first three
months, Pc 0.001. There was a slight rise of 22 25 mmole/24
hr from three to six months, P C 0.02. Analyzing the change
over the whole of the first six month period, the mean fall of 91
mmole/24 hr was still highly significant, P c 0.001.
Urine protein excretion was only in the frankly nephrotic
range for one patient (number 5) prior to the start of the trial (8.4
g124 hr). During the initial six months of the study there was a
mean fall of 1.1 g124 hr in the group as a whole, P C 0.05. The
patient with the heaviest proteinuria had a decrease of 5.3 g124
hr during this time.
There was a tendency for the plasma potassium to be raised
(5 to 6 mmole/liter) probably because of the high vegetable
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Fig. 2. Changes in the combined urea and creatinine clearance for each
patient. Lines connect the individual values obtained at the beginning
and end of the trial period. The numbers by each line are the patient
numbers as listed in Table 1.
content of the diet, but no patient required an ion—exchange
resin. Dietary advice rapidly corrected any values which were
greater than 6 mmole/liter.
Serum phosphate fell from 2.27 0.44 to 1.72 0.41
mmole/liter in the first three months of treatment, during which
no change was made in dosage of phosphate binders, P < 0.005.
During the initial six months of the study, the mean decrease in
phosphate of 0.58 mmole/liter remained statistically significant,
P < 0.05. In the six patients who had no change in their dose of
phosphate binding agent during this period, the fall in serum
phosphate of 0.55 mmole/liter was also significant, P < 0.01.
Corrected total serum calcium rose during the initial three
months by 0.17 0.2 mmole!liter, P < 0.02. Nine patients
received no alfacalcidol or calcium carbonate during this pe-
riod. Their rise of 0.19 0.2 mmole/liter was also significant, P
<0.02. By six months only six subjects had not been prescribed
alfacalcidol or calcium carbonate. Their mean value rose from
2.14 0.17 to 2.35 0.1 mmole/liter, P = 0.05. No patient
developed hypercalcemia at any time.
The calcium X phosphate product was also calculated. The
value fell by 0.96 (mmole/liter)2 during the first three months, P
<0.05. By six months the mean value had dropped from 4.85
1.02 to 3.84 1.07 (mmole/liter)2, P < 0.02.
Serum PTH levels were measured before and after the first
three months of treatment in 11 patients. Values fell in all, P <
0.01 (Fig. 3). Nine patients received no alfacalcidol during this
time and their values fell by 0.62 ng/mliter, P < 0.02.
The hemoglobin concentration remained constant throughout
the study period with no statistically significant changes. The
mean hemoglobin was 7.87 0.9 g/100 mliter at the start and
7.88 0.91 g/l00 mliter at six months.
Nutritional assessment
Body wt fell in 11 of the 12 patients during the first three
months. The mean loss was 3.3 kg, P <0.005. The maximum
individual loss was 7.1 kg during this time. Subsequently body
wt tended to be more stable. No further statistical analysis has
been carried out as several patients required diuretics for edema
later in the study.
Triceps skinfold (TSF) dropped by an average of 0.9 mm
during the initial three months, P < 0.005, though half the
patients had no measured change. From 0 to 6 months the mean
difference was — 1.4 mm, P < 0.02, though there was no change
in five of the group. The seven patients who were on the diet for
at least 12 months had a mean fall in TSF of 1 mm, P < 0.02,
although two of the group had no observed difference. Two
patients with initial falls in TSF regained their losses but no
subject showed an increase.
Mid-arm muscle circumference (MAMC) fell by a mean of 0.6
cm during the first three months, P < 0.02, but no change was
seen in six of the patients. By six months the mean fall was 0.9
cm, P < 0.005. Only three patients had no change during this
period. The seven patients studied for at least 12 months had a
mean decrease of 1.7 cm, P < 0.001. The maximum decline in
MAMC seen was 2.5 cm.
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Fig. 3. The changes in individual parathormone (PTH) levels expressed
in nglmliter during the first three months on the diet (N = 11).
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Serum albumin did not change significantly throughout the
study. All patients except one had normal values at the start,
mean 39.7 3.4 g/liter. The mean value at six months was 41.2
8.8 g/liter. The one patient with an initial low value, 30 g/liter,
had the heaviest proteinuria. Her serum albumin remained
steady throughout the 12 months of the study.
The mean transferrin level was 2.37 0.27 g/liter at the start
of treatment and 2.37 0.22 after 12 months (normal 2.0 to 4.0
glliter). There were no statistically significant changes in the
group as a whole at three, six or 12 months. Small individual
differences did not correlate with changes in MAMC.
Crealinine metabolism
As noted previously, the majority of patients had a fall in
plasma creatinine concentration during the first six months of
treatment. In two patients there was a striking association
between a fall in plasma creatinine of >300 molc/liter and an
estimated loss of muscle mass of 4 kg (Fig. 4).
The 24 hr urinary excretion of creatininc fell during the initial
three months, the mean value decreasing from 7. 14 2.55 to
5.8 1.33 mmole, 1' <0.001. Subsequently, creatinine output
remained stable. Over 12 months creatinine excretion fell from
7.98 1.77 to 5.81 1.44 mmole, N = 7, P <0.02.
In view of the observed loss of muscle circumference in the
majority of patients, the urinary creatinine excretion per 24 hr
in mmole was related to estimated muscle mass in kg. During
the first six months creatinine excretion per unit muscle mass
fell from 0.32 0.06 to 0.26 0.04 mmole/kg/24 hr, P < 0.005.
This represents a mean decrease of 21% (rangc 0 to 46%), most
of which occurred during the first three months.
Discussion
In view of the increasing number of studies which appear to
suggest that low protein diets significantly slow the progress of
chronic renal failure [211 the nephrologist might be tempted to
prescribe protein restriction for all patients with this condition.
It is clearly important, however, that the safety and efficacy of
such regimes should be fully tested before their general use is
recommended. Our study attempts to clarify some of these
issues in relation to very low nitrogen diets supplemented by
essential amino acids and keto acids.
Our experience confirms previous findings that those taking a
keto acid diet lose their uremic symptoms even in the face of
deteriorating renal function [221. There is, however, a minority
of subjects who find that the EAA/KAA mixture produces
intolerable nausea. This has been noted previously with similar
supplements 1231. We found no clinical evidence of an increased
incidence of uremic complications such as neuropathy or pen-
carditis, and Giovanetti [24] has reported that nerve conduction
may improve slightly in patients taking a similar regime.
The most important consideration from both a practical and
theoretical point of view is whether the diet affected renal
function. Arguably the most convenient method of assessing
changes in renal function is by use of the slope of reciprocal
plasma creatinine [25]. In most cases of chronic renal failure the
slope remains constant, provided no new factor such as hyper-
tension intervenes [261. Most previous studies of protein re-
striction have compared this slope before and after treatment
[10, 11, 14, 151. Using this criterion the majority of our patients
(S of 12) had a significant slowing in the rate at which renal
function was deteriorating. An alternative means of assessment
suggested by Mitch et al [14] is the "delay," or period of time
which elapses before the plasma creatinine again reaches its
starting value. The majority of our patients had considerable
delays, in two cases the delays were longer than 12 months.
Our data, however, suggest that the use of plasma creatinine
measurements (or their reciprocals) alone is unlikely to lead to
a valid assessment of renal function following the introduction
of regimes such as ours. The presence of the delay is caused by
the plasma creatinine falling, by over 300 imole/liter in some
cases, during the first few months of treatment. A correspond-
ing "hump" is therefore seen in the reciprocal plot. This
phenomenon also occurred to some ol' the patients in previous
studies, that is, patient number 20 in Mitch et a! 114] and patient
number 9 in Alvestrand et al [101.
Despite this fall in plasma creatinine, there was no improve-
ment in either creatinine clearance or combined urea and
creatininc clearance in any of our patients, even in the two
whose reciprocal slopes changed from negative to positive.
Thus this delay seems to he caused by an alteration in creatinine
metabolism rather than improvement in renal function.
At the low levels of renal function of our patients accurate
measurements of GFR are difficult to obtain on an outpatient
basis. Single shot isotopic techniques such as Cr51-EDTA
overestimate true GFR [271. Creatinine clearance or preferably
combined urea and creatinine clearance [17, 27] provide a better
measure. Few studies on the effects of a diet have reported
serial measurements of either of these clearances. Barsotti et al
[16] did show that the rate of decline of creatinine clearance was
much slower after starting a similar diet. In our study, an
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Fig. 4. A comparison between the changes in plasma creatinine
(,nmo!e/liter) and antliropometricallv derived total muscle mass (kg)
during the first six months on the diet in patients 5 and 6.
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inadequate number of clearances performed prior to starting the
diet prevented a meaningful analysis. Nevertheless the obser-
vation of only very small changes in GFR in four of our patients
over the 12 month period suggests a reduction in the rate of
deterioration.
An alternative means of assessing the effect of the regime
suggested by Mitch et at [14], is to compare the actual time
taken to reach an arbitrary creatinine value with that projected
from the pre-treatment reciprocal creatinine plot. With an
approximate assessment of the time "spared," renal replace-
ment therapy can then be derived. Using a plasma creatinine
value of 1500 mole/liter as an indication of the need to start
dialysis, our 12 subjects appeared to have been spared a total of
approximately four patient years of renal replacement therapy.
Mitch et al [14] reported that their patients on a comparable diet
had a similar extended period of freedom from dialysis treat-
ment. However, this method of assessment is still dependent on
plasma creatinine, and if this is lowered by non-renal mecha-
nisms, it may not be a realiable measure of the uremic state and
thus when to start renal replacement therapy.
The metabolic changes observed in our trial were similar to
those previously reported [22] with a marked fall in blood urea.
Urine urea excretion fell in parallel with the blood urea during
the first three months of treatment. The significant decline in
proteinuria is of interest in view of the recent report that the
response to a low protein diet correlated with the drop in
protein excretion in patients with glomerulonephritis [28].
There were insufficient numbers of subjects with this group of
diseases in our study to confirm this finding.
The changes in calcium and phosphate metabolism are of
considerable interest. There was a marked drop in serum
phosphate as noted previously [16, 23]. This was accompanied
by a small but significant rise in corrected total calcium.
Previously it has been reported that patients may develop
hypercalcemia with a similar diet [23] but this did not occur in
our experience. Despite the rise in calcium the calcium X
phosphate product fell as noted before [23]. PTH levels de-
clined in most patients as Barsotti et al [29] also found. Though
this fall may have been related to an improved calcium intake
from the keto acid salts, the total amount consumed by our
patients was only 0.39 mmole/kg/day (15.6 mg/kg/day). Frohling
and colleagues [30] reported a fall in parathormone when keto
acid supplements were used with moderate protein restriction.
livery low protein diets are to be regarded as safe it is necessary
to show that malnutrition does not occur [31]. A number of
different techniques have been used to assess nutritional status.
These include weight, anthropometry, serum protein levels and
nitrogen balance studies. The study of Barsotti et al [16] gave no
details of the nutritional effects of a nearly identical regime to ours.
Subsequently Giovanetti [24] claimed that serum protein levels,
including transferrin, remained normal and there was no change in
thigh muscle circumference. Mitch et al [14], using a diet given
slightly more nitrogen, noted no change in body wt and small rises
in serum transferrin and albumin. They did not report
anthropometric measurements but found a positive nitrogen bal-
ance. Kopple and colleagues [31], using a diet supplemented by
essential amino acids giving an even higher nitrogen intake,
reported no change in anthropometry. Our patients did lose wt
during the first three months of treatment, but serum albumin
remained absolutely normal and transferrin levels did not change
significantly.
However, there were marked discrepancies between the
direct muscle mass measurements and serum transferrin. Pa-
tients 5 and 6 apparently lost 4 kg each of muscle mass during
the first six months, having a drop in muscle circumference of at
least 2 cm. Yet both had persistently normal levels of serum
transferrin. Patient 4 had a rise in serum transferrin at the same
time as muscle mass decreased (data not shown). It might be
argued that there was a loss of nitrogen during the initial phase
of the diet but the muscle changes occurred gradually and not
suddenly. It is of course possible that the use of the keto acids
in different proportions might have avoided these nutritional
problems but we felt it important to use a regime which had
already been tried without any apparent serious side effects
[13]. Whatever the reason for the discrepancy between anthro-
pometry and the other measures of protein balance, this study
strongly suggests that assessment of the nutritional conse-
quences of a low protein diet must include direct measurements
of muscle mass by anthropometry since the other commonly
used techniques may not reveal significant losses.
We deliberately chose a high calorie intake as we were
concerned to minimize the catabolism of protein. Recent stud-
ies suggest that a safe minimum level for chronic renal failure
patients is 35 kcal/kg/day [32]. Yet despite our prescribed high
intake, there was no increase and sometimes a slight fall in body
fat. To maintain the level prescribed it was necessary for our
patients to consume calorie—containing supplements. It is pos-
sible that these were not always taken in sufficient amounts, but
assessment by the dietitian suggested that only one patient
consumed less than 30 kcallkg/day. Of the rest, nine took
consistently in excess of 36 kcal/kg/day.
We have noted above the drop in plasma creatinine occurring
with this and similar diets unaccompanied by improvements in
GFR. The implication is that the body creatinine pool had
somehow decreased. Several factors are likely to be involved:
the reduction in dietary creatinine, the loss of muscle mass and
possibly alterations in creatinine production or degradation.
Estimates of up to 30% have been made for the proportion of
creatinine produced from exogenous sources in normal subjects
[33]. However, some of our patients were already on protein
restriction before taking the diet and several were anorexic. In
two of our patients there was a striking parallelism between
plasma creatinine and anthropometrically assessed muscle
mass. However, in other patients this fall in creatinine occurred
in the absence of measurable changes in muscle circumference.
Our patients had a drop in urinary creatinine excretion per unit
muscle mass of 21% with individual changes of up to 46%,
suggesting altered creatinine metabolism. Endogenous creati-
nine is derived from creatine at a relatively fixed rate, the
process occurring non-enzymatically. Whether this rate of
hydrolysis can be changed is unknown. Creatinine is also
degraded in the body [34, 35] possibly in the gut [34]. This
degradation forms a significant proportion of creatinine metab-
olism in chronic renal failure [35]. Whether this process can be
altered is uncertain but it is possible there was a change in
bowel flora during the period on the diet. These alterations in
plasma creatinine, muscle mass and creatinine excretion all
appeared to occur in the first three to four months on the regime
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and may represent adaptation to it. A new steady—state appears
to be attained after this time.
In conclusion, whether the diet tested in our trial did appear
to slow the progression of renal failure is still uncertain. There
were, however, disadvantages including the loss of muscle
mass. The taking of this regime required considerable dedica-
tion on the part of the patients and their families as virtually
separate meals had to be prepared. We note that Mitch et al [141
spent a long time on patient education with a similar trial.
Several of our other chronic renal failure subjects declined the
diet because of its complexity. We, therefore, do not feel able to
recommend it for widespread use. We suspect that a less
restricted regime will find much wider patient acceptance with
fewer nutritional problems [31].
Our study revealed that variations in the reciprocal of plasma
creatinine do not provide a valid measure of changes in renal
function when very low protein diets are used. It is also suggested
that anthropometric measurements are essential in any assess-
ment of the nutritional consequences of such regimes.
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